GlassScriptPhysician profile
Angela M Bosch
NPI 1265509509
$7,161.43
in general payments reported to CMS, 2019-2025
29 companies · $1,491 in 2025
The $1,491 reported for 2025 was more than what 89% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $375 · 2022: $1,334 · 2023: $1,805 · 2024: $2,156 · 2025: $1,491.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,452.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,452.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,156.67 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $883.13 | 2022-2025 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $470.50 | 2021-2025 | Dupixent, Libtayo |
| Incyte Corporation | $461.62 | 2021-2025 | Opzelura |
| Novartis Pharmaceuticals Corporation | $430.74 | 2022-2025 | |
| Lilly USA, LLC | $428.08 | 2021-2025 | Ebglyss, Taltz, Olumiant |
| Janssen Biotech, INC. | $352.67 | 2021-2025 | Tremfya |
| Sun Pharmaceutical Industries INC. | $323.37 | 2021-2025 | Ilumya, Blu-U |
| Arcutis Biotherapeutics, INC. | $308.32 | 2023-2025 | Zoryve |
| Leo Pharma INC. | $281.65 | 2022-2025 | Adbry |
| Ucb, INC. | $250.67 | 2021-2025 | Bimzelx, Cimzia |
| Amgen INC. | $244.74 | 2021-2025 | Otezla, Otezla |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $236.59 | 2022-2025 | Cabtreo, Arazlo |
| Almirall LLC | $210.68 | 2021-2024 | Seysara, Klisyri |
| Dermavant Sciences, INC. | $190.25 | 2022-2024 | Vtama |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $189.60 | 2021-2025 | |
| Pfizer INC. | $152.91 | 2021-2023 | |
| Mayne Pharma Commercial LLC | $149.08 | 2021-2025 | |
| Galderma Laboratories, L.P. | $141.22 | 2021-2024 | Aklief |
| Boehringer Ingelheim Pharmaceuticals, INC. | $98.11 | 2022-2025 | Spevigo |
| Organon LLC | $61.45 | 2024-2025 | Vtama |
| Mallinckrodt Hospital Products INC. | $20.82 | 2025 | Acthar |
| Strata Skin Sciences, INC. | $19.92 | 2025 | Xtrac |
| Kerecis Limited | $18.79 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Epi Health, LLC | $18.19 | 2022 | |
| Verrica Pharmaceuticals INC. | $18.09 | 2024 | Ycanth |
| Kyowa Kirin, INC. | $16.97 | 2022 | |
| Janssen Pharmaceuticals, INC | $14.71 | 2024 | Tremfya |
| Biofrontera INC. | $11.89 | 2024 | Ameluz, Xepi, Bf-Rhodoled |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angela Bosch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.